Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Tlando (testosterone undecanoate) drug profile, 2024?

See the DrugPatentWatch profile for Tlando

Tlando® (testosterone undecanoate) – 2024 Drug Profile

Drug class:

  • Anabolic–androgenic steroid (AAS)
  • Long‑acting testosterone ester

Manufacturer:

  • T. – “Tlando” (formerly T-Health; see FDA drug code 2051)

Formulation & Strength:

  • Injectable oil suspension (ethanol–propylene glycol vehicle)
  • 200 mg/mL testosterone undecanoate
  • 1 mL vial (200 mg)

Routes of Administration:

  • Intramuscular (IM) injection (gluteal or ventro‑lateral thigh)

1. Indications

Indication Approved Dose & Schedule Key Points
Hypogonadal men (low endogenous testosterone) Initial: 200 mg IM × 2 weeks (or 1 month per manufacturer guidance)
Maintenance: 200 mg IM every 4 weeks (≈6 months)
• Effective in restoring serum testosterone to mid‑normal range (≈250–800 ng/dL).
• Must be used under supervision of a qualified clinician.
Gender‑affirming hormone therapy (female-to-male) Initiation: 200 mg IM 2 weeks apart (2–4 weeks)
Maintenance: 200 mg IM every 4 weeks
• Testosterone undecanoate provides sustained masculinization with minimal peaks.
Atypical or off‑label uses No official approval • Off‑label use (e.g., for athletic performance enhancement, muscle building) is discouraged due to safety concerns and regulatory restrictions.

Note: In 2024, Tlando remains FDA‑approved only for the above indications. The European Medicines Agency (EMA) has not granted a marketing authorization for any testosterone undecanoate product; physicians in the EU must rely on alternative preparations (e.g., testosterone enanthate, cypionate).


2. Mechanism of Action

  • Testosterone undecanoate is a long‑acting ester of testosterone.
  • After IM injection, the ester is hydrolyzed slowly by plasma esterases, releasing free testosterone over ~4–5 weeks.
  • Free testosterone binds to the androgen receptor (AR) in target tissues (muscle, bone, prostate, CNS) to modulate gene transcription and protein synthesis.

3. Pharmacokinetics (average values for 200 mg dose)

Parameter Value (approx.) Comments
Cmax 3–5 ng/mL (≈10–20 nmol/L) Occurs ~4–7 days post‑dose.
Tmax 4–7 days Due to slow ester hydrolysis.
Half‑life (t½) 4–5 weeks Reflects depot release rather than testosterone clearance.
AUC (0–∞) ~100 ng·day/mL Linear with dose.
Protein binding > 99 % to albumin and SHBG Saturation may occur with high doses.
Metabolism Primarily hepatic aromatization (to estradiol) and 5α‑reduction (to dihydrotestosterone).
Excretion Urine (conjugates) and feces (bile‑excretion).

Drug–Drug Interaction (DDI) Potential:
• Enzyme induction (CYP3A4) or inhibition can alter testosterone levels.
• Aromatase inhibitors (e.g., anastrozole) reduce estradiol conversion; may increase testosterone concentration.
• CYP3A4 inducers (e.g., rifampin, carbamazepine) may lower testosterone levels; consider dose adjustment.


4. Dosage & Administration

Population Starting Dose Maintenance Dose Titration Notes
Hypogonadal men 200 mg IM 2 weeks apart 200 mg IM every 4 weeks • Evaluate serum testosterone 2–4 weeks after the second injection.
• Adjust dose (e.g., 400 mg or 300 mg) if levels remain sub‑therapeutic (<250 ng/dL).
Gender‑affirming therapy 200 mg IM 2 weeks apart (2–4 weeks) 200 mg IM every 4 weeks • Monitor feminizing signs (e.g., breast size, body composition).
• Adjust per patient response.
Pregnancy/lactation Contraindicated N/A • Testosterone can cross placenta; avoid during pregnancy.
Elderly or hepatic impairment Start 200 mg IM 2 weeks apart 200 mg IM every 6 weeks (optional) • Monitor liver enzymes and testosterone levels closely.

Administration Technique
• Use a 22‑24 gauge needle and a 1‑2 mL syringe.
• Inject into the gluteus maximus or vastus lateralis.
• Rotate sites to minimize injection site reactions.


5. Contraindications

Category Specifics
Known hypersensitivity To testosterone, undecanoate ester, or any excipient.
Active prostate or breast cancer Testosterone can stimulate hormone‑responsive tumors.
Uncontrolled hypertension Testosterone may worsen blood pressure.
History of thromboembolic disease Testosterone can increase coagulability.
Untreated sleep apnea Testosterone may worsen apnoea.
Pregnancy/Lactation Testosterone crosses the placenta; avoid.

6. Precautions & Monitoring

Parameter Monitoring Frequency Target Notes
Serum total testosterone 2–4 weeks after 2nd dose, then every 6–8 weeks 300–800 ng/dL Adjust dose to stay within this range.
Prostate‑specific antigen (PSA) Every 6–12 months (men > 50 yr) ≤ 4 ng/mL Monitor for prostate pathology.
Liver function tests Every 3–6 months AST/ALT ≤ 2 × ULN Avoid in severe hepatic disease.
Hemoglobin/hematocrit Every 3–6 months Hematocrit ≤ 50 % (men) Red blood cell count can rise; watch for polycythemia.
Blood pressure Every visit < 140/90 mmHg Treat hypertension as needed.
Lipid profile Every 6–12 months LDL < 130 mg/dL Testosterone may modestly worsen lipids.
Estradiol Optional < 40 pg/mL May guide aromatase inhibitor use.
Signs of androgen excess Every visit N/A Monitor acne, hirsutism, voice changes.

Important: Do not exceed 400 mg/IM if serum testosterone > 800 ng/dL to avoid supraphysiologic levels.


7. Adverse Reactions (Common ≥ 5 %, Rare < 1 %)

System Typical Symptoms Management
Endocrine Acne, oily skin, hirsutism, gynecomastia (in females) Topical retinoids, anti‑androgens, consider dose reduction.
Hematologic Polycythemia, erythrocytosis Phlebotomy, reduce dose, or stop therapy.
Cardiovascular Elevated blood pressure, edema Monitor BP, consider antihypertensives.
Psychiatric Mood swings, aggression, insomnia Counsel, consider dose adjustment.
Gastro‑intestinal Injection site pain, myalgias Warm compress, rotate sites.
Reproductive Decreased sperm count, infertility (male) Discuss fertility desires; may need sperm banking.
Liver Elevated transaminases Monitor LFTs; stop if > 3 × ULN.
Allergic Rash, anaphylaxis (rare) Discontinue, treat with antihistamines/epinephrine.

8. Drug Interactions

| Drug/Agent | Interaction Type | Clinical Impact | Mitigation |



Other Questions About Tlando :

tlando vs jatenzo What is tlando? Tlando vs jatenzo? Tlando price per month? Tlando price? Tlando precio? Tlando?